Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study.
We studied effects of i.v. atilmotin (BAX-ACC-1638, a novel motilin agonist, circulating t(1/2) < 10 min) on gastrointestinal transit in humans using a randomized, parallel-group, dose-response double-blind study of i.v. atilmotin, 6, 30, 60 microg or vehicle (placebo) given 2 min after standardized breakfast, lunch and dinner. The breakfast meal contained (99m)Tc-eggs and (111)In-milk. Full gastrointestinal transit was measured by scintigraphy. Primary endpoints were % gastric emptying (GE) at 30 min, GE t(1/2), colonic filling (CF) at 6 h, and geometric centre of colonic transit at 24 h. Analysis included adjustment for age, gender and body mass index, with Bonferroni correction applied for multiple comparisons. A significant treatment effect of atilmotin was detected for GE (%) at 30 min for solids and liquids (P < 0.01 for both). There were no significant effects on CF or CT and no significant adverse clinical events. Thus, atilmotin accelerates GE of solids and liquids in healthy humans. These data suggest that, at the doses tested, atilmotin should be considered for treatment of stomach motility disorders.
Park
M-I
MI
Clinical Enteric Neuroscience Translational and Epidemiological Research C.E.N.T.E.R. Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Ferber
I
I
Camilleri
M
M
Allenby
K
K
Trillo
R
R
Burton
D
D
Zinsmeister
A R
AR
D000293:Adolescent; D000328:Adult; D000368:Aged; D003106:Colon / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000494:pharmacology*; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009037:Motilin / Q000378:metabolism / Q000494:pharmacology*; D010446:Peptide Fragments / Q000378:metabolism / Q000494:pharmacology*; D019518:Postprandial Period
D005765:Gastrointestinal Agents; D010446:Peptide Fragments; C508748:atilmotin; D009037:Motilin